Wave Life Sciences’ Phase II open-label trial investigating its disease-modifying drug for boys living with Duchenne Muscular ...

Several companies will head to the FDA seeking approval of new Duchenne muscular dystrophy treatments next year but the death of a patient taking Sarepta’s Elevidys raises important safety questions.

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for ...

Proven financial leader brings decades of experience in capital allocation, business development and shareholder value creation - WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics ...

Regenxbio has reported positive interim data from the Phase I/II portion of its Affinity Duchenne study, which is examining ...

The company plans to submit a Biologics Licence Application to the US Food and Drug Administration later in 2025 for its DMD ...

Dyne is eyeing an accelerated approval filing for DYNE-251 in early 2026 that would pit the asset against Sarepta’s Exondys ...

The Phase I/II Deliver trial sought to establish the impact of DYNE-251 on several mobility-related endpoints, seeing an ...

Dyne Therapeutics (NASDAQ:DYN) on Monday  reported new long-term clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 demonstrating “unprecedented and sustained functional improvement at ...

Detailed price information for Dyne Therapeutics Inc (DYN-Q) from The Globe and Mail including charting and trades.

Dyne Therapeutics (DYN) announced new long-term clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 demonstrating unprecedented ...

The collaboration between Silly Nice and CJEI is driven by a shared commitment to economic justice. As New York's cannabis ...